|
Gene: TF |
Gene summary for TF |
Gene summary. |
Gene information | Species | Human | Gene symbol | TF | Gene ID | 7018 |
Gene name | transferrin | |
Gene Alias | HEL-S-71p | |
Cytomap | 3q22.1 | |
Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | A0PJA6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7018 | TF | P8T-E | Human | Esophagus | ESCC | 1.25e-10 | 4.06e-01 | 0.0889 |
7018 | TF | P10T-E | Human | Esophagus | ESCC | 1.42e-06 | -5.41e-02 | 0.116 |
7018 | TF | P16T-E | Human | Esophagus | ESCC | 1.60e-16 | 2.50e-01 | 0.1153 |
7018 | TF | P22T-E | Human | Esophagus | ESCC | 2.40e-03 | -8.78e-02 | 0.1236 |
7018 | TF | P57T-E | Human | Esophagus | ESCC | 9.24e-21 | 1.12e+00 | 0.0926 |
7018 | TF | P74T-E | Human | Esophagus | ESCC | 2.85e-03 | 1.43e-01 | 0.1479 |
7018 | TF | P76T-E | Human | Esophagus | ESCC | 5.67e-12 | 8.38e-01 | 0.1207 |
7018 | TF | P128T-E | Human | Esophagus | ESCC | 5.02e-19 | 1.31e+00 | 0.1241 |
7018 | TF | NAFLD1 | Human | Liver | NAFLD | 1.33e-14 | 1.52e+00 | -0.04 |
7018 | TF | S43 | Human | Liver | Cirrhotic | 1.96e-06 | 4.81e-01 | -0.0187 |
7018 | TF | HCC1_Meng | Human | Liver | HCC | 7.28e-77 | 1.16e+00 | 0.0246 |
7018 | TF | HCC2_Meng | Human | Liver | HCC | 6.25e-19 | -6.79e-01 | 0.0107 |
7018 | TF | cirrhotic1 | Human | Liver | Cirrhotic | 3.69e-15 | -1.70e-01 | 0.0202 |
7018 | TF | cirrhotic2 | Human | Liver | Cirrhotic | 1.67e-15 | -1.87e-01 | 0.0201 |
7018 | TF | cirrhotic3 | Human | Liver | Cirrhotic | 2.61e-02 | -4.09e-01 | 0.0215 |
7018 | TF | HCC1 | Human | Liver | HCC | 7.61e-40 | 8.09e+00 | 0.5336 |
7018 | TF | HCC2 | Human | Liver | HCC | 6.48e-53 | 8.08e+00 | 0.5341 |
7018 | TF | HCC5 | Human | Liver | HCC | 3.83e-07 | 4.78e+00 | 0.4932 |
7018 | TF | Pt13.a | Human | Liver | HCC | 1.44e-27 | 2.57e-01 | 0.021 |
7018 | TF | Pt13.b | Human | Liver | HCC | 8.21e-34 | 3.51e-02 | 0.0251 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00436242 | Liver | HCC | cellular protein complex disassembly | 71/7958 | 136/18723 | 1.39e-02 | 4.95e-02 | 71 |
GO:200123332 | Liver | Cyst | regulation of apoptotic signaling pathway | 26/496 | 356/18723 | 3.37e-06 | 2.71e-04 | 26 |
GO:009719132 | Liver | Cyst | extrinsic apoptotic signaling pathway | 16/496 | 219/18723 | 2.55e-04 | 8.70e-03 | 16 |
GO:200123531 | Liver | Cyst | positive regulation of apoptotic signaling pathway | 10/496 | 126/18723 | 1.93e-03 | 4.13e-02 | 10 |
GO:200123631 | Liver | Cyst | regulation of extrinsic apoptotic signaling pathway | 11/496 | 151/18723 | 2.32e-03 | 4.60e-02 | 11 |
GO:00098968 | Lung | IAC | positive regulation of catabolic process | 114/2061 | 492/18723 | 4.93e-15 | 1.25e-11 | 114 |
GO:00313318 | Lung | IAC | positive regulation of cellular catabolic process | 98/2061 | 427/18723 | 7.79e-13 | 9.25e-10 | 98 |
GO:20012338 | Lung | IAC | regulation of apoptotic signaling pathway | 82/2061 | 356/18723 | 4.85e-11 | 1.44e-08 | 82 |
GO:00165704 | Lung | IAC | histone modification | 93/2061 | 463/18723 | 5.41e-09 | 8.03e-07 | 93 |
GO:00020648 | Lung | IAC | epithelial cell development | 52/2061 | 220/18723 | 6.75e-08 | 6.91e-06 | 52 |
GO:00485458 | Lung | IAC | response to steroid hormone | 69/2061 | 339/18723 | 2.99e-07 | 2.34e-05 | 69 |
GO:00105066 | Lung | IAC | regulation of autophagy | 65/2061 | 317/18723 | 4.97e-07 | 3.14e-05 | 65 |
GO:00316478 | Lung | IAC | regulation of protein stability | 62/2061 | 298/18723 | 5.37e-07 | 3.32e-05 | 62 |
GO:00713837 | Lung | IAC | cellular response to steroid hormone stimulus | 47/2061 | 204/18723 | 6.27e-07 | 3.72e-05 | 47 |
GO:20012368 | Lung | IAC | regulation of extrinsic apoptotic signaling pathway | 38/2061 | 151/18723 | 7.33e-07 | 4.14e-05 | 38 |
GO:00614586 | Lung | IAC | reproductive system development | 79/2061 | 427/18723 | 2.39e-06 | 1.06e-04 | 79 |
GO:00616147 | Lung | IAC | pri-miRNA transcription by RNA polymerase II | 19/2061 | 55/18723 | 3.20e-06 | 1.38e-04 | 19 |
GO:00486086 | Lung | IAC | reproductive structure development | 78/2061 | 424/18723 | 3.44e-06 | 1.44e-04 | 78 |
GO:00971918 | Lung | IAC | extrinsic apoptotic signaling pathway | 47/2061 | 219/18723 | 5.11e-06 | 2.03e-04 | 47 |
GO:00420608 | Lung | IAC | wound healing | 76/2061 | 422/18723 | 1.01e-05 | 3.23e-04 | 76 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0406629 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa04066113 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
hsa0435014 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0421621 | Liver | Cirrhotic | Ferroptosis | 23/2530 | 41/8465 | 4.09e-04 | 2.57e-03 | 1.58e-03 | 23 |
hsa0406612 | Liver | Cirrhotic | HIF-1 signaling pathway | 46/2530 | 109/8465 | 4.00e-03 | 1.59e-02 | 9.78e-03 | 46 |
hsa0421631 | Liver | Cirrhotic | Ferroptosis | 23/2530 | 41/8465 | 4.09e-04 | 2.57e-03 | 1.58e-03 | 23 |
hsa0406613 | Liver | Cirrhotic | HIF-1 signaling pathway | 46/2530 | 109/8465 | 4.00e-03 | 1.59e-02 | 9.78e-03 | 46 |
hsa0421641 | Liver | HCC | Ferroptosis | 33/4020 | 41/8465 | 1.42e-05 | 9.88e-05 | 5.50e-05 | 33 |
hsa0406622 | Liver | HCC | HIF-1 signaling pathway | 70/4020 | 109/8465 | 2.96e-04 | 1.36e-03 | 7.57e-04 | 70 |
hsa0421651 | Liver | HCC | Ferroptosis | 33/4020 | 41/8465 | 1.42e-05 | 9.88e-05 | 5.50e-05 | 33 |
hsa0406632 | Liver | HCC | HIF-1 signaling pathway | 70/4020 | 109/8465 | 2.96e-04 | 1.36e-03 | 7.57e-04 | 70 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TF | SNV | Missense_Mutation | c.1906N>T | p.Gly636Cys | p.G636C | P02787 | protein_coding | deleterious(0.01) | possibly_damaging(0.767) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
TF | SNV | Missense_Mutation | novel | c.693N>T | p.Glu231Asp | p.E231D | P02787 | protein_coding | tolerated(0.09) | benign(0.138) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TF | SNV | Missense_Mutation | c.1009N>C | p.Glu337Gln | p.E337Q | P02787 | protein_coding | tolerated(0.24) | benign(0.03) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
TF | SNV | Missense_Mutation | c.1565N>C | p.Leu522Pro | p.L522P | P02787 | protein_coding | tolerated(0.35) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
TF | SNV | Missense_Mutation | novel | c.1816N>C | p.Val606Leu | p.V606L | P02787 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TF | SNV | Missense_Mutation | novel | c.1073G>T | p.Cys358Phe | p.C358F | P02787 | protein_coding | deleterious(0.05) | benign(0.097) | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TF | SNV | Missense_Mutation | novel | c.161N>T | p.Pro54Leu | p.P54L | P02787 | protein_coding | tolerated(0.06) | possibly_damaging(0.843) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
TF | SNV | Missense_Mutation | c.1907N>T | p.Gly636Val | p.G636V | P02787 | protein_coding | tolerated(0.05) | benign(0.375) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TF | SNV | Missense_Mutation | c.493C>G | p.Leu165Val | p.L165V | P02787 | protein_coding | tolerated(0.45) | benign(0.035) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TF | insertion | Frame_Shift_Ins | novel | c.2011_2012insCCTCTGGGGGAACAACCACTCA | p.Gly671AlafsTer17 | p.G671Afs*17 | P02787 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | adalimumab | ADALIMUMAB | 27115882 | |
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | Ademetionine | ADEMETIONINE | ||
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | CALAA-01 | |||
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | PF-06763809 | |||
7018 | TF | CELL SURFACE, DRUGGABLE GENOME | EP-2167 |
Page: 1 |